ProLNG-001 / Progeneer - LARVOL DELTA

An Idiotype Vaccine Strategy Utilizing Targeted NGS and Cell Free Protein Synthesis System Ensures Identification and Production of Human Idiotype Antigens, and Shows Promising Results in Preclinical Models of B-Cell Lymphoma with a Novel TLR7/8 Agonist-Based Adjuvant and Anti-PD-L1 Antibody (ASH 2023) - "The liposomal adjuvant ProLNG-001 (TLR7/8 agonist 140 μg) and ProLNG-002 (TLR7/8 agonist 70 μg + TLR4 agonist 5 ug) were synthesized by microfluidics method...Atezolizumab 10 mg/kg was administered intraperitoneally 3 times a week for 3 weeks in the idiotype vaccine + immune checkpoint inhibitor combination group (Figure 1a)... Taken together, the idiotype vaccine strategy using targeted NGS for BCR, CFPS system for idiotype antigen manufacturing, and TLR7/8-agonist-based liposomal adjuvants showed highly effective results in the preclinical syngeneic A20 tumor model. Furthermore, the usage of immune checkpoint inhibitors combined with idiotype vaccine in B cell lymphoma may exert synergistic effects. The CFPS system can be applied to swift, robust and personalized manufacturing of idiotype antigen for individuals with different idiotype sequence in a GMP setting, which was not possible in prior studies."

IO biomarker • Next-generation sequencing • Preclinical • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • TLR4

In-situ generation of cancer antigens with prolonged TLR7/8 agonist immunomodulator for cancer therapy in preclinical model (ESMO-BC 2024) - "These results indicate an improvement in the TME and suggest the induction of systemic immunity, ultimately leading to a significantly enhanced anti-cancer therapeutic effect. Conclusions Our data suggest that an intra-tumoral ProLNG-001 combined with conventional chemotherapy could emerge as an effective anti-cancer immunomodulator in TNBC."

Immunomodulating • Preclinical • Oncology • Triple Negative Breast Cancer